WAM
CLDX icon

Wolverine Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Wolverine Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-37
Closed -$40K – 1851
2014
Q4 		$40K Sell
37
-4
-10% -$994 ﹤0.01% 1454
2014
Q3 		$100K Buy
41
+37
+925% +$8.06K ﹤0.01% 1300
2014
Q2 		$19K Sell
4
-3
-43% -$677 ﹤0.01% 1699
2014
Q1 		$75K Sell
7
-1
-13% -$383 ﹤0.01% 1213
2013
Q4 		$48K Sell
8
-21
-72% -$8.09K ﹤0.01% 1780
2013
Q3 		$18K Buy
+29
New +$9.94K ﹤0.01% 2056

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wolverine Asset Management's CLDX Position: Q1 2015 in Review

Wolverine Asset Management sold out of Celldex Therapeutics (CLDX) in Q1 2015, closing a stake of 140 shares — an estimated $50.1K sold.

Wolverine Asset Management first reported a position in CLDX in Q4 2013 and held it in 4 quarters. The position peaked at $401K in Q4 2013. 193 funds tracked by Wall St. Rank hold CLDX as of Q1 2015.

  • Wolverine Asset Management reported no remaining Celldex Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Wolverine Asset Management sold 140 Celldex Therapeutics shares in Q1 2015, an estimated $50.1K.
  • Wolverine Asset Management first reported a position in Celldex Therapeutics in Q4 2013 and held it in 4 quarters.
  • Wolverine Asset Management's Celldex Therapeutics position peaked at $401K in Q4 2013.
  • 193 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2015.

Based on Wolverine Asset Management's 13F filing for Q1 2015, filed 15 May 2015.